ライフサイエンスコーパス: CD4 count

1 med similarly, irrespective of HIV status or CD4 count.

2 tracted study sample size, year(s), and mean CD4 count.

3 immediate initiation of ART, irrespective of CD4 count.

4 n age at cancer diagnosis by AIDS status and CD4 count.

5 co, where viral loads are higher for a given CD4 count.

6 ome isolates were positively correlated with CD4 count.

7 virologically suppressed patients with high CD4 count.

8 patients with intermediate and high baseline CD4 counts.

9 with HIV load and negatively correlated with CD4 counts.

10 ommended, with earlier ART in those with low CD4 counts.

11 ssion by reducing viral loads and increasing CD4 counts.

12 nexpensive, robust, user-friendly method for CD4 counting.

13 ore advanced disease in South Africa (median CD4 count 102, 213, and 172 cells/microl in South Africa

14 men, median age 37 years (IQR 30-44), median CD4 count 156 cells per muL (61-253), median plasma HIV

15 an immunodeficiency virus coinfected (median CD4 count 16 cells/microL [interquartile range, 6-40]).

16 Of the remaining 1177 patients (median CD4 count 165 cells per muL [IQR 75-271]), 163 (14%) had

17 fected subjects from Thailand (mean baseline CD4 count, 188 cells/microL; mean viral load, 5.4 log10

18 ween May 8, 2013 and August 29, 2014 (median CD4 count 210 cells/mm3).

19 uted blocks of size eight, and stratified by CD4 count (220-349 cells per muL vs >/=350 cells per muL

20 ith HIV with advanced disease (baseline mean CD4 count, 262 cells/mm(3)) before and up to 3 years aft

21 ractices (adjusted difference of square root CD4 count 3.1, 95% CI -1.2 to 7.4; p=0.16);); in a pre-p

22 lack, 13% Hispanic; median age was 37 years, CD4 count 321 cells/microL, and viral load 4.5 log10 cop

23 In addition, a lower CD4 count (350-499) at baseline was associated with a ri

24 participants started therapy at enrollment (CD4+ count, 350 to 550 cells per cubic millimeter).

25 50 copies/mL; 99% on antiretrovirals; median CD4 count: 489 cells/microL; HCV treatment naive 29%; HC

26 th retention than not having an ART-eligible CD4 count (50% versus 32%), an intention-to-treat risk d

27 Sixty patients were included (median CD4 count 53 cells/microL (interquartile range [IQR], 22

28 ted children (median age, 13.8 years; median CD4 count, 770 x 10(6) cells/L; 83% with undetectable HI

29 th retention than not having an ART-eligible CD4 count (91% versus 21%), a complier causal risk diffe

30 eiving antiretroviral therapy; 136 (21%) had CD4 counts above 350 cells per muL and had never receive

31 ation antiretroviral therapy (cART) with low CD4 counts achieve viral suppression but not CD4 cell re

32 Nadir and enrollment CD4 counts, activated T-cells, and time on ART were simi

33 rugs, ART initiation year, and baseline age, CD4 count, AIDS, duration of ART) all-cause and cause-sp

34 no significant associations with viral load, CD4 counts, AIDS, cancer, or mortality in both cohorts b

35 CD4 counts also vary widely within individuals and among

36 ion, after adjustment for maternal HIV load, CD4 count and cART exposure (adjusted odds ratio, 3.51;

37 ded better AMI and mortality prediction than CD4 count and HIV-1 RNA, suggesting that current health

38 not started ART, did not have AIDS, and had CD4 count and HIV-RNA viral load measurements within 6 m

39 Lack of correlation with CD4 count and IgG level suggests that susceptibility to

40 on to HIV disease-related factors, including CD4 count and viral load (VL), are unknown.

41 g extended Cox regression models with recent CD4 count and VL analyzed as time-changing covariates.

42 mine risk of subsequent NMSCs in relation to CD4 count and VL.

43 trong correlation between CCR5 CRPA and both CD4 counts and CD4 T cell apoptosis.

44 stingly, CCR5 CRPA correlated inversely with CD4 counts and CD4:CD8 ratio specifically in viremic pat

45 Although 1-year post-HCT median CD4 counts and freedom from IV immunoglobulin were impro

46 buted by patients who received ART, had high CD4 counts and had undetectable HIV RNA, whereas inciden

47 reduces detectable viral load, and increases CD4 counts and hemoglobin levels in pregnant HIV-infecte

48 response relationship between risk and lower CD4 counts and higher VLs.

49 CD4 counts and human immunodeficiency virus (HIV) load t

50 Over time, KS and NHL occurred at higher CD4 counts and lower HIV RNA values, and KS occurred mor

51 We compared HIV RNA levels, CD4 counts and percentages, lipids, and growth across gr

52 ised to monitoring with or without 12-weekly CD4 counts and to receive 2 nucleoside reverse transcrip

53 ak positive correlation was observed between CD4+ counts and missing teeth (rho = 0.380, P <0.05), CD

54 rtunistic oral lesions along with records of CD4+ counts and viral load levels were evaluated in 29 i

55 art [HR 1.58, 95% CI 1.47-1.69], most recent CD4 count) and retention (ART club membership, baseline

56 PLWH and examines associations between AIDS, CD4 count, and age at cancer diagnosis.

57 ated outcome measures, including viral load, CD4 count, and CD4/CD8 ratio.

58 ock size 4) and was stratified by HIV-1 RNA, CD4 count, and region (USA or ex-USA).

59 race, HIV risk group, calendar year, cohort, CD4 count, and viral load.

60 h HIV who received effective ART, had higher CD4 counts, and had suppressed HIV RNA and not by increa

61 rated rapid, point-of-care HIV screening and CD4 counts, and in-parallel viral load testing, to promo

62 pdated and cumulative measures of HIV-1 RNA, CD4 counts, and the VACS Index.

63 ciparum infection status, hemoglobin levels, CD4 counts, and viral load in pregnant, HIV-positive wom

64 able changes in subjects' hemoglobin levels, CD4 counts, and viral loads, particularly with helminth

65 n multivariable analysis, entry FIB-4, entry CD4(+) count, and cumulative alcohol use remained signif

66 nterval, 1.34-2.86]), adjusted for age, sex, CD4(+) count, and World Health Organization disease stag

67 ) T(SCM) predicted lower viral loads, higher CD4(+) counts, and less CD8(+) T cell activation.

68 Plasma viral load and CD4 counts are effective for clinical monitoring, but th

69 IV) in HIV-infected pregnant women with high CD4 counts are lacking.

70 e with the costs of the drugs themselves and CD4 counts are measured every 6 months, but patients are

71 nterval [CI], -10.7 to 22.4 cells/year), nor CD4 count at ART initiation (beta = -1.1 cells/year; 95%

72 tion (N = 295 455) and 71 articles reporting CD4 count at ART initiation (N = 549 702).

73 (95% CI, 9.2-70.2 cells/year; P = .02), but CD4 count at ART initiation did not change.

74 Mean CD4 count at ART initiation was 154/muL.

75 The mean CD4 count at ART initiation was 261 cells/microL before

76 oor CD4 count documentation and lower median CD4 count at ART initiation was associated with increase

77 conclusion, the CRF01_AE subtype and a lower CD4 count at baseline tend to be associated with the fas

78 multiplicatively with transmission routes or CD4 count at baseline to contribute to HIV/AIDS progress

79 aches by population reached, HIV positivity, CD4 count at diagnosis and linkage.

80 Median CD4 count at diagnosis of HIV infection was 376 cells pe

81 Mean CD4 count at diagnosis was 356 cells per muL (SD 254) in

82 cases in categories of ART use, HIV RNA, and CD4 count at diagnosis were described across calendar ti

83 The primary outcome was CD4 count at diagnosis.

84 this high-income setting with relatively low CD4 count at HIV diagnosis.

85 During 2002-2013, neither CD4 count at presentation (beta = 5.8 cells/year; 95% co

86 We identified 56 articles reporting CD4 count at presentation (N = 295 455) and 71 articles

87 studies conducted in South Africa (N = 14), CD4 count at presentation increased by 39.9 cells/year (

88 l-based comparison between current standard (CD4 count at presentation of 0.260 x 109 cells/L, univer

89 at baseline) mortality rate ratios (MRRs) by CD4 count at start of ART (0-49, 50-99, 100-199, 200-349

90 T, there was a strong inverse association of CD4 count at start of ART with mortality.

91 CD4 count at start of combination antiretroviral therapy

92 oss of LTNP status was associated with lower CD4 counts at 10 years after seroconversion (p < 0.0001)

93 CD4 counts at presentation to care and at ART initiation

94 Median CD4 counts at randomisation were 442 (IQR 373-522) cells

95 Estimated CD4 counts at seroconversion for a typical individual de

96 Median CD4 counts at switching were 215 cells per muL (IQR 117-

97 de comparisons, patients with TAMs had lower CD4 counts at treatment initiation than did patients wit

98 After adjustment for age, sex, CD4 count before therapy, and WHO stage, the sample-corr

99 ns occurred more frequently among those with CD4 counts below 200 cells/muL.

100 306) entering clinical HIV care with a first CD4 count between 12 August 2011 and 31 December 2012 in

101 els, while adjusting for peak HIV RNA, nadir CD4(+)count, CD4/CD8 ratio, CMV IgG levels, time from ED

102 ine which laboratory parameters (viral load, CD4 count, CD8 count, CD4 %, CD8 %, CD4/CD8) are most st

103 Among patients with CD4 counts close to the 350-cells/mul threshold, having

104 f patients who started ART with low baseline CD4 count converged with mortality of patients with inte

105 QR 30-42), 11 628 (34%) were men, and median CD4 count count before therapy was 154 cells per muL (IQ

106 CD4 count decreased by a median of -130 cells per muL (r

107 e-initiation group) or to defer it until the CD4+ count decreased to 350 cells per cubic millimeter o

108 fewer women on ART, and in cohorts with poor CD4 count documentation and lower median CD4 count at AR

109 cumented transfers, and in cohorts with poor CD4 count documentation, whereas higher patient load was

110 Mean CD4 count dropped by 39.6% at 3 months and 46.7% at 6 mo

111 a higher steady state viral load and larger CD4 count drops.

112 Studies suggest that CD4 counts early in HIV infection do not predict relevan

113 n HIV care than patients who just missed the CD4-count eligibility cutoff.

114 ipants started therapy after two consecutive CD4+ counts fell below 250 cells per cubic millimeter or

115 The decision to start ART was determined by CD4 count for one in four patients (25%) presenting clos

116 CD4 counts for ART initiation were necessary when medica

117 eroid response, whereas a larger increase in CD4+ count from baseline to 1 to 3 months corresponded t

118 IV-1 RNA greater than 5000 copies per mL and CD4 counts greater than 200 cells per muL were randomly

119 Furthermore, individuals with HIV-1 with CD4 counts greater than 200 cells/mm(3) displayed higher

120 513 (71%) participants had CD4 counts greater than 300 cells per muL and were recei

121 nce of active tuberculosis, and had baseline CD4 counts greater than 350 cells per muL if they had ne

122 -1-infected adults on ART for >/= 18 mo with CD4 count > 350 cells/mm3 in a malaria-endemic region in

123 ated costs averted if ART was initiated at a CD4 count >/=200 cells/microL were estimated using Joint

124 cted pregnant women (</=28 weeks' gestation, CD4 count >/=200 cells/microL, hemoglobin level >/=7 g/L

125 10, who were followed from the date they had CD4 count >/=350 cells/muL and were virologically suppre

126 1.86-3.61) compared with those who achieved CD4 count >200 cells/microL.

127 period were risk factors for not achieving a CD4 count >200 cells/microL.

128 1.08-1.34, p = 0.001), and having a baseline CD4 count >350 cells/uL (HR 2.37, 95% CI 1.94-2.89.

129 s aged 18-70 years with controlled HIV (with CD4 counts >200 cells per muL and HIV-1 RNA <200 copies

130 contacts of HIV-infected index patients with CD4 counts >250 cells/microL and contacts of index patie

131 chronic HEV infection can persist despite a CD4(+) count >200 cells/mm(3).

132 s on suppressive antiretroviral therapy with CD4+ counts >350 cells/muL and detectable plasma HIV-1 R

133 ated HIV/AIDS progression compared to higher CD4 count (>/=500) (HR = 4.38, 95%CI: 1.95-9.82, P < 0.0

134 remain demethylated, despite restoration of CD4+ counts (>/=800 cells per mm(3)) with antiretroviral

135 starting such therapy in patients after the CD4+ count had declined to 350 cells per cubic millimete

136 While the dynamics and correlates of CD4 counts have been well documented, the same does not

137 continuation after ART-induced recovery with CD4 counts higher than 350 cells per muL reduced admitta

138 ter <1:64; HR, 1.94 [95% CI, 1.58-2.39]) and CD4 counts (HR, 1.07 for every 100-cell increase [95% CI

139 ("rapid arm") received a point-of-care (POC) CD4 count if needed; those who were ART-eligible receive

140 The mean estimated CD4 count in 2002 was 251 cells/microL at presentation a

141 ophylaxis should be provided irrespective of CD4 count in settings with a high burden of infectious d

142 be transmitted and affect the viral load and CD4 count in the recipient.

143 ectrochemical magneto-actuated biosensor for CD4 count in whole blood.

144 h spans the whole medical interest range for CD4 counts in AIDS patients.

145 HHC was significantly associated with higher CD4 counts in patients.

146 e given to ART initiation at higher absolute CD4 counts in such populations to optimize the impact of

147 and immediate access to ART irrespective of CD4 count, in order to optimize the impact of ART.

148 anges were independent of viral replication, CD4 counts, inflammation, and type of antiretroviral tre

149 at all people living with HIV, regardless of CD4 count, initiate antiretroviral therapy (ART) upon di

150 etection, no ART or delayed initiation (when CD4 count is <0.350 x 109 cells/L), reduced investment i

151 TION: Decreasing monitoring to annually when CD4 count is higher than 200 cells per muL compared with

152 al therapy (ART), virologic suppression, and CD4 count is important.

153 n retention between patients presenting with CD4 counts just above versus just below the 350-cells/mu

154 28% versus 46% had CD4 count less than 200 cells per muL (0.60, 0.32 to 1.1

155 than 350 cells per muL, and proportion with CD4 count less than 200 cells per muL.

156 L (lower limit of normal) and 11 (55%) had a CD4 count less than 200 cells/muL; 11 (55%) subjects had

157 al therapy prior to admission, and 80% had a CD4 count less than 200.

158 ractices versus 73% in control practices had CD4 count less than 350 cells per muL (risk ratio 0.75,

159 muL was 2 days shorter (95% CI 1-2) and at a CD4 count less than 350 cells per muL was 5 days shorter

160 omes were rate of diagnosis, proportion with CD4 count less than 350 cells per muL, and proportion wi

161 than 500 cells per muL, and initiation at a CD4 count less than 350 cells per muL, respectively.

162 than 500 cells per muL, and initiation at a CD4 count less than 350 cells per muL.

163 L, and 1.06 (1.04-1.08) with initiation at a CD4 count less than 350 cells per muL.

164 t 7 years with a strategy of initiation at a CD4 count less than 500 cells per muL was 2 days shorter

165 (95% CI 1.01-1.02) when ART was started at a CD4 count less than 500 cells per muL, and 1.06 (1.04-1.

166 AIDS: immediate initiation, initiation at a CD4 count less than 500 cells per muL, and initiation at

167 T with immediate initiation, initiation at a CD4 count less than 500 cells per muL, and initiation at

168 reening test for people living with HIV with CD4 count less than or equal to 350 cells per muL who ar

169 osis prevalence and in susceptible patients (CD4 counts less than 200 cells per muL) detection of cho

170 s compared with participants with HIV-1 with CD4 counts less than 200 cells/mm(3).

171 TB-IRIS patients and controls had similar CD4 counts, levels of T-cell-associated immune activatio

172 adults with HIV, who were naive to ART, had CD4 count lower than 100 cells per muL and HIV RNA great

173 Better clinical status (higher CD4 counts, lower viral loads and activation) was associ

174 deferred ART eligibility, as determined by a CD4 count < 350 cells/mul, per South African national gu

175 ) and from 40%/35% to 13%/13% for cases with CD4 count </= 350 cells/mm3 or AIDS (all p < 0.001).

176 om 39%/62% to 94%/90% among individuals with CD4 count </= 350 cells/mm3 or AIDS (all p < 0.001).

177 In the control arm, 42.3% (83/196) had a CD4 count </= 350 cells/mul at first visit, of whom 92.8

178 initiation of ART within 3 mo in those with CD4 count </= 350 cells/mul did not differ significantly

179 ered according to national guidelines, i.e., CD4 count </= 350 cells/mul) contributed to the first ph

180 nds routinely screening AIDS patients with a CD4 count </=100 cells/microL for cryptococcal infection

181 unodeficiency virus-infected patients with a CD4 count </=100 cells/microL to detect and treat early

182 ses, including 6 stratified by preenrollment CD4 count </=200 cells/muL, were analyzed and compared t

183 Sixteen (80%) subjects had a CD4 count </=441 cells/muL (lower limit of normal) and 1

184 aled that a previous diagnosis with CM and a CD4 count </=50 cells/microL were significantly associat

185 Health Organization Stage 1 or 2 disease and CD4 count </=500 cells/mm3.

186 In regression modeling, having a CD4 count </=700 cells/mm(3) contributed to a 2.1 mm Hg

187 have an IOP </=10 mm Hg, and patients with a CD4 count </=700 cells/mm(3) were 13 times more likely t

188 st that the addition of "HIV infected with a CD4 count <100 cells/microL" to the EORTC host criteria

189 oma diagnosis (difference = 4; P = .01), and CD4 count <200 cells/microL (vs >/=500) was associated w

190 n with HIV RNA load >10 000 copies/mL and/or CD4 count <200 cells/microL had lower rates of seroconve

191 biomarker of more severe immune deficiency (CD4 count <200 cells/mL) had a 44% increased risk of sub

192 P < .01) and more likely to have a pregnancy CD4 count <200 cells/mm3 (19% vs 11%, P = .01).

193 orld Health Organization stage 4 event (with CD4 count <250) was 0.96 (95% confidence interval (CI):

194 of subtype C-infected women progressed to a CD4 count <350 cells/microL within 2 years of infection.

195 Fifty-one of 1452 participants with baseline CD4 count <350 cells/muL developed IRIS.

196 ccurred mainly in patients starting ART with CD4 count <50 cells/microl.

197 ld Health Organization treatment guidelines (CD4 count <500 cells/microL) would require most individu

198 in 645 HIV-positive, ART-naive patients with CD4 counts </=100 cells/microL in Cape Town, South Afric

199 h active pulmonary tuberculosis and baseline CD4 counts </=125 cells/microL initiating ART.

200 o ADCs and NADCs were highest for PWHIV with CD4 counts <100 cells/mm3.

201 In those with HIV, longer exposure to CD4 counts <200 cells/microL, and, to a lesser extent, h

202 ized HIV-infected tuberculosis patients with CD4 counts <350 cells/microL were included; tuberculosis

203 ), and 14% (95% CI, 2%-25%) among those with CD4 counts <350, 350-499, and >/=500 cells/microL, respe

204 ed with prevalent anal HR-HPV infection were CD4(+)count <350/muL (odds ratio, 2.9; 95% confidence in

205 -cells/mul threshold, having an ART-eligible CD4 count (<350 cells/mul) was associated with higher 12

206 0 copies per mL, or >400 000 copies per mL), CD4 count (<50 cells per muL, 50-199 cells per muL, or >

207 The limit of detection for the CD4 counting magneto-actuated biosensor in whole blood w

208 Increasing age, lower initial CD4 count, male heterosexual and injection drug use tran

209 d with lack of cancer treatment included low CD4 count, male sex with injection drug use as mode of H

210 fits of offering immediate ART regardless of CD4 count may be larger than suggested by clinical trial

211 Absolute CD4 counts may play a role in IOP fluctuations.

212 ver, current evidence suggests that although CD4 counts may still play a role in guiding clinical car

213 Viral load levels, CD4+ nadir, and CD4+ counts may present a weak to moderate correlation t

214 In contrast to the CD4 count, measurement of the level of HIV RNA in plasma

215 n, lower baseline eGFR, female gender, lower CD4 count nadir, hypertension, diabetes, and cardiovascu

216 after 1 month of tuberculosis treatment at a CD4 count of <100 cells/mm(3) or World Health Organizati

217 viduals with HIV infection (age >/=18 years, CD4 count of <200 cells per muL, ART naive) and randomly

218 fter 2 months of tuberculosis treatment at a CD4 count of 100-350 cells/mm(3).

219 re high risk, 74% had stage III to IV BL and CD4 count of 195 cells per muL (range, 0-721 cells per m

220 age 56.3%) newly accessed care with a median CD4 count of 250 cells/mul (interquartile range 159-426)

221 5 (15%) were positive for HIV, with a median CD4 count of 41 (8-167).

222 Enrolled participants had median CD4 count of 636 cells per muL, median HIV DNA 170 copie

223 HIV-1 RNA of at least 1000 copies per mL, a CD4 count of at least 100 cells per muL, and estimated g

224 pressive antiretroviral therapy with current CD4 count of at least 350 cells per muL and HIV DNA betw

225 ) on a stable regimen for at least 6 months, CD4 count of more than 100 cells per muL, and no history

226 ith no change in the previous 12 weeks and a CD4 count of more than 100 cells per muL.

227 = 2.4, 95% CI: 1.3, 4.3) than in those with CD4 counts of >/=100 (hazard ratio = 1.1, 95% CI: 0.8, 1

228 h CDM versus LCM was greater in persons with CD4 counts of <100 (hazard ratio = 2.4, 95% CI: 1.3, 4.3

229 The strategies were defined by the threshold CD4 counts of 200 cells per muL, 350 cells per muL, and

230 with linkage to care with ART initiation at CD4 counts of 350 cells per muL or less reduces HIV inci

231 5 years with ART initiation for people with CD4 counts of 350 cells per muL or less.

232 axis should be given with ART in people with CD4 counts of 350 cells per muL or lower in low-income a

233 [HR] 0.40, 95% CI 0.26-0.64) when started at CD4 counts of 350 cells per muL or lower with antiretrov

234 Expansion of ART eligibility CD4 counts of 350-500 cells per muL is cost-effective at

235 V-positive without AIDS, ART-naive, and with CD4 counts of 500 cells per muL or higher.

236 ntiretroviral therapy to adult patients with CD4 counts of 500 cells per muL or less ranged from $237

237 ncentrations of at least 1000 copies per mL, CD4 counts of at least 200 cells per muL, estimated glom

238 women at 14 or more weeks of gestation with CD4 counts of at least 350 cells per cubic millimeter to

239 estricted to person-time accrued on ART with CD4 counts of at least 500 cells per muL and when white

240 e than 10 000 copies per mL among those with CD4 counts of more than 350 cells per muL was cost-effec

241 Expansion of ART to people with CD4 counts of more than 350 cells per muL who also have

242 For individuals with CD4 counts of more than 350 cells per muL, we compared i

243 Median CD4 counts of the latter 2 groups were 150 and 93 cells/

244 total of 2056 patients (41% with a baseline CD4+ count of >/=500 cells per cubic millimeter) were fo

245 hazard ratio among patients with a baseline CD4+ count of >/=500 cells per cubic millimeter, 0.56; 9

246 hazard ratio among patients with a baseline CD4+ count of >/=500 cells per cubic millimeter, 0.61; 9

247 ents, including those with cirrhosis, with a CD4+ count of 200/mm3 or greater or CD4+ percentage of 1

248 4), including 68 in patients with a baseline CD4+ count of at least 500 cells per cubic millimeter (3

249 ed previous ART and were starting ART with a CD4+ count of fewer than 100 cells per cubic millimeter.

250 ticipants who had HIV type 1 infection and a CD4+ count of less than 800 cells per cubic millimeter a

251 World Health Organization stage 4 events, a CD4+ count of more than 250 cells per cubic millimeter,

252 odeficiency virus (HIV) infection who have a CD4+ count of more than 350 cells per cubic millimeter.

253 oviral therapy in HIV-positive adults with a CD4+ count of more than 500 cells per cubic millimeter p

254 domly assigned HIV-positive adults who had a CD4+ count of more than 500 cells per cubic millimeter t

255 end points (68%) occurred in patients with a CD4+ count of more than 500 cells per cubic millimeter.

256 no IPT, both overall and among patients with CD4+ counts of at least 500 cells per cubic millimeter.

257 e, and postpartum HIV care engagement (>/= 1 CD4 count or viral load [VL] test within 90 days of deli

258 , evidence of treatment failure based on one CD4 count or viral load measurement ranged from 86 (32%)

259 y), associated with retention in care (>/= 1 CD4 count or VL test in each 6-month interval of the per

260 ted individuals, particularly those with low CD4 counts or high VLs.

261 d this outcome appeared to be independent of CD4+ count or WHO stage.

262 th detectable HIV viremia and inversely with CD4 count (p<0.0001), consistent with HIV activation of

263 nd HIV risk group (p<0.0001); higher pre-ART CD4 count (p=0.0008) and pre-ART viral load (p=0.0003) w

264 proportion of KS and NHL occurred at higher CD4 counts (P < .05 for KS and NHL) and with undetectabl

265 2,243 to 1,355,998 HIV-1 RNA copies/ml) and CD4 counts (range, 26 to 801 cells/mm(3)).

266 use (HR, 1.37 [95% CI, 1.02-1.85], P = .04), CD4(+) count (risk per 100-cell increase: HR, 0.90 [95%

267 rt prophylaxis for opportunistic infections, CD4 counts should cease to be required for ART initiatio

268 and identified HIV-positive people at higher CD4 counts than facility testing.

269 Comparing randomized groups by 48-week CD4 count, the mortality risk associated with CDM versus

270 long-term ART, 308/378 (81%) monitored with CD4 counts versus 297/375 (79%) without had VL <1,000 co

271 , sex, age, year of ART initiation, baseline CD4 count, viral load, and AIDS status, before and after

272 Measured CD4 count, VL, and subsequent NMSC (BCC and SCC).

273 33% were non-Hispanic black, and the median CD4 count was 0.341 x 109 cells/L.

274 antiretroviral therapy (ART), and the median CD4 count was 149 cells/microL.

275 d 4 of 12 patients, respectively, and median CD4 count was 161 (101-188) cells/microL and 167 (135-13

276 copies/mL) in 32 patients (80%); the median CD4 count was 249/muL (range, 39-797).

277 Median CD4 count was 310 cells per muL (IQR 179-424).

278 Median CD4 count was 333 cells/microL, and 23% of patients had

279 seline median VL was 4.5 log10 copies/mL and CD4 count was 390 cells/microL.

280 Median CD4 count was 424 cells per muL (IQR 268-606) in the int

281 Median CD4 count was 430 (IQR, 190-620) cells/microL.

282 and without stable residence had HIV; median CD4 count was 514 cells per muL (IQR 355-703).

283 The median CD4 count was 530 cells per cubic millimeter among 3490

284 Median CD4 count was 577 (interquartile range, 397-820) cells/m

285 The median baseline CD4 count was 748 (interquartile range, 481-930) cells/m

286 The mean 12-month increase in CD4 count was 8.15 (95% CI, -.13 to 16.43) cells/microL

287 n this subpopulation, having an ART-eligible CD4 count was associated with higher 12-month retention

288 tion between CMV load in saliva and maternal CD4 count was observed (r = -0.495, n = 22, P = .019).

289 dian age was 45 years, 77% were male, median CD4(+) count was 561 cells/microL, and brachial FMD was

290 Median CD4(+) count was 655 cells/microL and HIV load was <50 c

291 ars), almost 62% were female, and the median CD4+ count was 173 cells/mul (IQR 92-254 cells/mul).

292 years, 53.7% were women, and median baseline CD4+ count was 240 cells/mm3.

293 nts, 311 (77%) had HIV infection; the median CD4+ count was 340 cells per cubic millimeter (interquar

294 The median baseline CD4+ count was 37 cells per cubic millimeter, but 854 pa

295 12,759 copies per milliliter, and the median CD4+ count was 651 cells per cubic millimeter.

296 ios rose to >/=1 in 35% of patients, whereas CD4 counts went >/=500/microl in 75%.

297 ositive HIV test or first treatment-eligible CD4 count were randomized to standard or rapid initiatio

298 bles measured at each study visit except for CD4 counts, which were lower (P < .05) in the latter gro

299 secutively recruited CM patients with normal CD4 counts who achieved microbiologic control.

300 /270) of the women who were HIV-positive had CD4 counts within National Department of Health ART init